Augelux Therapeutics

Augelux Therapeutics is a preclinical-stage biotechnology company dedicated to developing transformative therapies for blinding retinal diseases. Founded through a collaboration between Deerfield Management and the Johns Hopkins University School of Medicine, the company leverages the pioneering research of Dr. Peter Campochiaro. Augelux focuses on the Hypoxia-Inducible Factor (HIF) pathway to address the underlying drivers of neovascularization and vascular leakage in the eye. By inhibiting HIF, the company aims to suppress multiple angiogenic factors simultaneously, potentially offering superior durability and efficacy over current anti-VEGF monotherapies. The company's lead programs are designed to reduce the treatment burden for patients with conditions such as wet age-related macular degeneration and diabetic macular edema.